Group 1 - The company reported a revenue of 3.5242 million yuan for the first half of 2025, representing a year-on-year growth of 7.18% [1] - The net loss attributable to shareholders of the listed company was 39.6531 million yuan, with a net loss of 42.9408 million yuan after deducting non-recurring gains and losses [1] - The basic loss per share was 0.32 yuan [1]

Core Viewpoint - Jindike (688670) reported a revenue of 3.5242 million yuan for the first half of 2025, reflecting a year-on-year growth of 7.18%, but recorded a net loss attributable to shareholders of 39.6531 million yuan, with a basic earnings per share of -0.32 yuan [1] Financial Performance - The company achieved an operating revenue of 3.5242 million yuan in the first half of 2025 [1] - Year-on-year revenue growth was 7.18% [1] - The net profit attributable to shareholders was -39.6531 million yuan [1] - Basic earnings per share stood at -0.32 yuan [1]

证券代码：688670 证券简称：金迪克 公告编号：2025-023 江苏金迪克生物技术股份有限公司 关于 2025 年"提质增效重回报"专项行动方案的 半年度评估报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 报告期内，公司持续提升经营质量，在疫苗生产、批签发、研发、销售、经 营管理等方面实现成果如下： 1、加快四价流感疫苗生产与批签发进度，提高市场份额 2025 年 2 月底，WHO 召开专家会议宣布 2025-2026 年度北半球流感疫苗推 荐毒株组分，公司根据推荐毒株组织安排生产。本年度公司提前排产，加强设备 维护维修与车间环境保持，加强各部门协调配合，进一步提高生产效率。 公司目前可商业化生产的流感疫苗车间只有一条原液生产线，四种流感病毒 1 亚型原液的生产只有在依次完成后，才能进行制剂的配制、灌装和包装，生产周 期比有多条原液生产线的流感疫苗企业长。公司在建的四价流感病毒裂解疫苗车 间年设计产能为 3000 万支，新车间建成后，不仅可以提升产能，更可缩短生产 周期，有助于公司未来加快流感疫苗产品上市销售， ...

江苏金迪克生物技术股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688670 证券简称：金迪克 公告编号：2025-022 重要内容提示： 会议召开时间：2025 年 9 月 3 日（星期三）13:00-14:00 会议召开地点：上海证券交易所"上证路演中心"网络平台（网址： http://roadshow.sseinfo.com/） 会议召开方式：图文显示（可选）+网络文字互动方式 投资者可于 2025 年 9 月 2 日（星期二）17:00 前将有关问题通过电子邮 件、传真的形式发送至公司邮箱 gdk001@gdkbio.com。公司将在业绩说明会上 对投资者普遍关注的问题进行回答。 江苏金迪克生物技术股份有限公司（以下简称"公司"）将于 2025 年 8 月 22 日在《上海证券报》《中国证券报》《证券时报》《证券日报》及上海证券交 易所网站（www.sse.com.cn）披露《江苏金迪克生物技术股份有限公司 2025 年 半年度报告》及《江苏金 ...

证券代码：688670 证券简称：金迪克 公告编号：2025-021 具体情况如下： 单位：万元 | 项目 | 金额 | | --- | --- | | 募集资金总额 | 121,396.00 | | 减：券商承销佣金及保荐费 | 6,349.19 | | 收到募集资金总额 | 115,046.81 | | 减：以募集资金置换预先投入自筹资金的金额 | 14,596.29 | | 减：以募集资金置换预先支付发行费用的金额 | 342.30 | | 减：支付不含税发行费用的金额 | 1,136.90 | | 减：直接投入募集项目的金额 | 88,846.20 | | 减：购买理财产品、定期存款及结构性存款余额 | 5,500.00 | 1 经中国证券监督管理委员会证监许可[2021]1877 号文核准，并经上海证券交 易所同意，本公司由主承销商中信证券股份有限公司于 2021 年 7 月 21 日向社会 公众公开发行普通股（A 股）股票 2,200.00 万股，每股面值 1.00 元，每股发行 价人民币 55.18 元。截至 2021 年 7 月 27 日止，本公司共募集资金 1,213,960,000.00 ...

证券代码：688670 证券简称：金迪克 公告编号：2025-020 江苏金迪克生物技术股份有限公司 经审议，监事会认为公司 2025 年半年度报告及其摘要的编制和审议程序符 合相关法律法规及《公司章程》等内部规章制度的规定；公司 2025 年半年度报 告的内容和格式符合中国证监会和上海证券交易所的规定，所包含的信息能从 各个方面真实反映出公司 2025 年上半年度的经营管理和财务状况等事项；半年 度报告编制过程中，未发现公司参与半年度报告编制和审议的人员有违反保密 规定的行为；监事会全体成员保证公司 2025 年半年度报告披露的信息真实、准 确、完整，不存在任何虚假记载、误导性陈述或重大遗漏，并对其内容真实性、 准确性和完整性依法承担法律责任。全体监事一致同意通过该报告。 表决结果：同意票 3 票，反对票 0 票，弃权票 0 票。 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的 《江苏金迪克生物技术股份有限公司 2025 年半年度报告》和《江苏金迪克生物 技术股份有限公司 2025 年半年度报告摘要》。 第二届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不 ...

Core Viewpoint - The company, Jindike (688670.SH), reported a revenue increase of 7.18% year-on-year, but still faced a net loss, indicating challenges in profitability despite revenue growth [1] Financial Performance - The company achieved an operating revenue of 3.5242 million yuan, reflecting a year-on-year increase of 7.18% [1] - The net profit attributable to the parent company was -39.6531 million yuan, showing a year-on-year reduction in losses by 2.97% [1] - The net profit attributable to the parent company, after deducting non-recurring gains and losses, was -42.9408 million yuan, with a year-on-year reduction in losses of 8.92% [1] Market Opportunity - The domestic penetration rate of quadrivalent influenza vaccines is significantly lower than that of foreign markets, indicating substantial growth potential [1] - The company aims to capitalize on the steady growth of the influenza vaccine market in China by ensuring product quality and actively pursuing sales transformation [1] - The sales strategy focuses on deepening market penetration, enhancing service to end users, and expanding the incremental market to increase market share in the influenza vaccine sector [1]

江苏金迪克生物技术股份有限公司2025 年半年度报告 公司代码：688670 公司简称：金迪克 江苏金迪克生物技术股份有限公司 2025 年半年度报告 1/166 江苏金迪克生物技术股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 五、 公司负责人余军、主管会计工作负责人黄强及会计机构负责人（会计主管人员）黄强声明： 保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 不适用 公司已在本报告中详细阐述公司在经营过程中可能面临的各种风险，敬请查阅本报告第三节 "管理层讨论与分析"中"风险因素"的相关内容。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及公司未来计划，发展战略等前瞻性描述，不构成对投资者的实质承诺，敬请投 资者注意投资风险。 ...

| 交易日 | 融资净买入(元) | 融资余额(元) | 占流通市值比 | | --- | --- | --- | --- | | 2025-08-20 | 31.61万 | 2246.67万 | 1.08% | | 2025-08-19 | 177.14万 | 2215.06万 | 1.05% | | 2025-08-18 | 104.70万 | 2037.92万 | 1.02% | | 2025-08-15 | 47.58万 | 1933.22万 | 0.98% | | 2025-08-14 | -145.46万 | 1885.64万 | 0.96% | | 交易日 | 两融余额(元) | 余额变动(元) | 变动幅度 | | --- | --- | --- | --- | | 2025-08-20 | 2246.67万 | 31.61万 | 1.43% | | 2025-08-19 | 2215.06万 | 177.14万 | 8.69% | | 2025-08-18 | 2037.92万 | 104.70万 | 5.42% | | 2025-08-15 | 1933.22万 | 47.58万 | 2. ...

Group 1 - DJI launched the Osmo 360, entering the 360-degree camera market dominated by Insta360 [1][2] - Osmo 360 sold out within an hour of its release, indicating strong demand and competition in the market [2][4] - The introduction of Osmo 360 has prompted Insta360 to lower the price of its latest model, Insta360 X5, by 500 yuan, narrowing the price gap to under 300 yuan [2][4] Group 2 - Insta360 has successfully leveraged social media to create viral content, enhancing brand visibility and user engagement [10][12] - The rise of short video platforms has significantly increased the demand for unique and portable imaging devices like Insta360 [13][14] - The outdoor activity market has expanded, driving the demand for action cameras, with the outdoor equipment market growing from 67.5 billion yuan in 2019 to 87.2 billion yuan in 2023 [17][22] Group 3 - Insta360's market share reached 67% in the global 360-degree camera market as of 2023, showcasing its strong position [25] - The company has focused on making its products user-friendly, allowing consumers to easily create and share content [26][27] - Insta360's marketing strategy relies on user-generated content and social media engagement rather than traditional advertising [28][45] Group 4 - Insta360's revenue for 2024 is projected at 5.574 billion yuan, with a compound annual growth rate of 65.25% over the past three years [47] - The global 360-degree camera market is expected to grow from 13.814 billion dollars in 2023 to 81.335 billion dollars by 2030, with a compound annual growth rate of 28.8% [47] - The company plans to invest in R&D and expand its product offerings to maintain its competitive edge [49][50] Group 5 - Insta360 faces ongoing legal challenges from GoPro regarding patent infringements, which could impact its operations in the U.S. market [51][52] - The company is expanding its global presence, particularly in North America, where it has seen significant website traffic [50] - The focus on enhancing user experience through offline retail and workshops has proven effective in converting interest into sales [43][44]